G Michael Felker, Scott D Solomon, Marco Metra, John J V McMurray, Rafael Diaz, Brian Claggett, David E Lanfear, Hans Vandekerckhove, Tor Biering-Sørensen, Renato D Lopes, Alexandra Arias-Mendoza, Shin-Ichi Momomura, Ramon Corbalan, Felix J A Ramires, Faiez Zannad, Stephen B Heitner, Punag H Divanji, Stuart Kupfer, Fady I Malik, John R Teerlink
BACKGROUND: Omecamtiv mecarbil improves outcomes in patients with heart failure and reduced ejection fraction (HFrEF). We examined the relationship between baseline troponin, change in troponin over time, and the treatment effect of omecamtiv mecarbil in patients enrolled in the Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF) trial (NCT02929329). METHODS: GALACTIC-HF was a double-blind, placebo-controlled trial that randomized 8256 patients with symptomatic HFrEF to omecamtiv mecarbil or placebo...
January 10, 2024: Journal of Cardiac Failure